Cargando…
An open-label randomized clinical trial to evaluate the efficacy of everolimus versus tacrolimus in triple maintenance immunosuppressive therapy for kidney transplant patients
Tacrolimus (TAC), a calcineurin inhibitor, and everolimus (EVL), an mTOR inhibitor, have been used as immunosuppressive (ISS) drugs in post-kidney transplantation therapy. The objective of this study was to compare the efficacy of EVL vs TAC in the ISS maintenance triple therapy. Ninety-seven kidney...
Autores principales: | Assis, B.P.S., Lasmar, M.F., Fabreti-Oliveira, R.A., Araujo, S.A., Oliveira, J., Wanderley, D.C., Nascimento, E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Associação Brasileira de Divulgação Científica
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931813/ https://www.ncbi.nlm.nih.gov/pubmed/33681893 http://dx.doi.org/10.1590/1414-431X20209369 |
Ejemplares similares
-
Impact of maintenance immunosuppressive therapy on the fecal microbiome of renal transplant recipients: Comparison between an everolimus- and a standard tacrolimus-based regimen
por: Zaza, Gianluigi, et al.
Publicado: (2017) -
Tacrolimus-induced gingival hyperplasia and recovery from tacrolimus to everolimus switching
por: Oral, Alihan, et al.
Publicado: (2019) -
Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients
por: de Boer, S. E., et al.
Publicado: (2021) -
Efficacy and Safety of Low-Dose Everolimus as Maintenance Immunosuppression in Cardiac Transplant Recipients
por: Fuchs, Uwe, et al.
Publicado: (2012) -
Effects of immunotherapy induction on outcome and graft survival of kidney-transplanted patients with different immunological risk of rejection
por: Lasmar, Marcus Faria, et al.
Publicado: (2019)